MedTrace Logo

Clinical Outcome of Triheptanoin Treatment in Patients With Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) Treated Under Expanded Access Program

NCT03768817 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2020-08-28

No results posted yet for this study

Summary

The primary objective of the study is to evaluate the clinical outcomes for the trigger event of patients who receive triheptanoin in the emergency Investigational New Drug (eIND) program.

Conditions

  • Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)

Interventions

OTHER

No Intervention

This is a non-interventional retrospective medical record review study. No study investigational product will be administered in this protocol.

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Ultragenyx Pharmaceutical Inc

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-30
Primary Completion
2020-06-08
Completion
2020-06-08

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03768817 on ClinicalTrials.gov